Second-line treatment for primary central nervous system lymphoma

Research output: Contribution to journalArticle

Abstract

Failure after first-line treatment was reported in 35-60% of immunocompetent patients with primary central nervous system lymphoma (PCNSL). There are currently no reports focusing on salvage therapy. This review analyses prognostic factors and the efficacy of salvage therapy by focusing on data from papers reporting results of first-line treatment in 355 cases. The study group consisted of 173 patients presenting treatment failure. The interval between failure and death (TTD) was compared for age at relapse (≤ 60 vs > 60 years), type of failure (relapse vs progression), time to relapse (≤ 12 vs > 12 months) and salvage treatment (yes vs no). Median TTD was similar in younger and older patients (P = 0.09). Relapsed patients had a longer TTD than patients with progressive disease (P = 0.002). Early relapse led to a shorter TTD than late relapse (P = 0.005). Median TTD was 14 months for patients who underwent salvage therapy and 2 months for untreated cases (P <0.00001). A multivariate analysis showed an independent prognostic role for salvage therapy and time to relapse. Age and type of failure had no predictive value. Salvage therapy significantly improves outcome and, possibly, quality of life. As many different treatments were used conclusions cannot be made regarding an optimal treatment schedule.

Original languageEnglish
Pages (from-to)530-534
Number of pages5
JournalBritish Journal of Cancer
Volume79
Issue number3-4
DOIs
Publication statusPublished - 1999

Fingerprint

Salvage Therapy
Lymphoma
Central Nervous System
Recurrence
Therapeutics
Treatment Failure
Appointments and Schedules
Research Design
Multivariate Analysis
Quality of Life

Keywords

  • Brain neoplasms
  • Extranodal lymphomas
  • Non-Hodgkin's lymphoma
  • Primary central nervous system lymphoma
  • Salvage treatment

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Second-line treatment for primary central nervous system lymphoma. / Reni, M.; Ferreri, A. J M; Villa, E.

In: British Journal of Cancer, Vol. 79, No. 3-4, 1999, p. 530-534.

Research output: Contribution to journalArticle

@article{1c6d76b2e89d4353b485064540125765,
title = "Second-line treatment for primary central nervous system lymphoma",
abstract = "Failure after first-line treatment was reported in 35-60{\%} of immunocompetent patients with primary central nervous system lymphoma (PCNSL). There are currently no reports focusing on salvage therapy. This review analyses prognostic factors and the efficacy of salvage therapy by focusing on data from papers reporting results of first-line treatment in 355 cases. The study group consisted of 173 patients presenting treatment failure. The interval between failure and death (TTD) was compared for age at relapse (≤ 60 vs > 60 years), type of failure (relapse vs progression), time to relapse (≤ 12 vs > 12 months) and salvage treatment (yes vs no). Median TTD was similar in younger and older patients (P = 0.09). Relapsed patients had a longer TTD than patients with progressive disease (P = 0.002). Early relapse led to a shorter TTD than late relapse (P = 0.005). Median TTD was 14 months for patients who underwent salvage therapy and 2 months for untreated cases (P <0.00001). A multivariate analysis showed an independent prognostic role for salvage therapy and time to relapse. Age and type of failure had no predictive value. Salvage therapy significantly improves outcome and, possibly, quality of life. As many different treatments were used conclusions cannot be made regarding an optimal treatment schedule.",
keywords = "Brain neoplasms, Extranodal lymphomas, Non-Hodgkin's lymphoma, Primary central nervous system lymphoma, Salvage treatment",
author = "M. Reni and Ferreri, {A. J M} and E. Villa",
year = "1999",
doi = "10.1038/sj.bjc.6690083",
language = "English",
volume = "79",
pages = "530--534",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "3-4",

}

TY - JOUR

T1 - Second-line treatment for primary central nervous system lymphoma

AU - Reni, M.

AU - Ferreri, A. J M

AU - Villa, E.

PY - 1999

Y1 - 1999

N2 - Failure after first-line treatment was reported in 35-60% of immunocompetent patients with primary central nervous system lymphoma (PCNSL). There are currently no reports focusing on salvage therapy. This review analyses prognostic factors and the efficacy of salvage therapy by focusing on data from papers reporting results of first-line treatment in 355 cases. The study group consisted of 173 patients presenting treatment failure. The interval between failure and death (TTD) was compared for age at relapse (≤ 60 vs > 60 years), type of failure (relapse vs progression), time to relapse (≤ 12 vs > 12 months) and salvage treatment (yes vs no). Median TTD was similar in younger and older patients (P = 0.09). Relapsed patients had a longer TTD than patients with progressive disease (P = 0.002). Early relapse led to a shorter TTD than late relapse (P = 0.005). Median TTD was 14 months for patients who underwent salvage therapy and 2 months for untreated cases (P <0.00001). A multivariate analysis showed an independent prognostic role for salvage therapy and time to relapse. Age and type of failure had no predictive value. Salvage therapy significantly improves outcome and, possibly, quality of life. As many different treatments were used conclusions cannot be made regarding an optimal treatment schedule.

AB - Failure after first-line treatment was reported in 35-60% of immunocompetent patients with primary central nervous system lymphoma (PCNSL). There are currently no reports focusing on salvage therapy. This review analyses prognostic factors and the efficacy of salvage therapy by focusing on data from papers reporting results of first-line treatment in 355 cases. The study group consisted of 173 patients presenting treatment failure. The interval between failure and death (TTD) was compared for age at relapse (≤ 60 vs > 60 years), type of failure (relapse vs progression), time to relapse (≤ 12 vs > 12 months) and salvage treatment (yes vs no). Median TTD was similar in younger and older patients (P = 0.09). Relapsed patients had a longer TTD than patients with progressive disease (P = 0.002). Early relapse led to a shorter TTD than late relapse (P = 0.005). Median TTD was 14 months for patients who underwent salvage therapy and 2 months for untreated cases (P <0.00001). A multivariate analysis showed an independent prognostic role for salvage therapy and time to relapse. Age and type of failure had no predictive value. Salvage therapy significantly improves outcome and, possibly, quality of life. As many different treatments were used conclusions cannot be made regarding an optimal treatment schedule.

KW - Brain neoplasms

KW - Extranodal lymphomas

KW - Non-Hodgkin's lymphoma

KW - Primary central nervous system lymphoma

KW - Salvage treatment

UR - http://www.scopus.com/inward/record.url?scp=0032949685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032949685&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6690083

DO - 10.1038/sj.bjc.6690083

M3 - Article

C2 - 10027325

AN - SCOPUS:0032949685

VL - 79

SP - 530

EP - 534

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 3-4

ER -